The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

• Tipo: Artigo em Revista Científica Internacional
• Data: 2020

Autores

De Mello, RA (Autor) Outra; Neves, NM (Autor) Outra; Amaral, GA (Autor) Outra; Lippo, EG (Autor) Outra; Castelo Branco, P (Autor) Outra; Daniel Pozza (Autor) FMUP; Tajima, CC (Autor) Outra; Antoniou, G (Autor) Outra

Revista

Título: Journal of Clinical Medicine

Vol. 61

Página Final: 1918

ISSN: 2077-0383

Editora: MDPI

Indexação

ISI Web of Knowledge - 12 Citações

Classificação Científica

CORDIS: Ciências da Saúde

FOS: Ciências médicas e da saúde

Outras Informações

ID Authenticus: P-00S-HSX

DOI: 10.3390/jcm9061918

Abstract (EN): Introduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients.Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected.Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text.Conclusion: Emibetuzumab could be used for NSCLC cases with highMETexpression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 16